Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson(Hôpital Pontchaillou), Jean‐Marie Michot(Institut Gustave Roussy)
Cited by 105
Related Papers
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
|Nature Cancer|2020|119
How to manage patients with corticosteroids in oncology in the era of immunotherapy?
|European Journal of Cancer|2020|87
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
|Annals of Oncology|2021|81